Newsroom

November 05, 2018

Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded a two-year, Small Business Innovation Research contract to fund the company’s discovery pipeline for treatment of Crohn’s Disease and other autoimmune diseases. This project will be developed in partnership with Dr. Sara Lustigman at the New York Blood Center.

Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, “We are extremely grateful to the NIAID for their support of this program. We now have an important opportunity to collaboratively translate Dr. Lustigman’s innovative research in order to identify future therapies for autoimmune diseases.”

Dr. Sara Lustigman, Head of Laboratory at the Lindsley F. Kimball Research Institute at the New York Blood Center and a Scientific Founder at Celdara Medical, noted, “Identification of optimized tolerogenic compounds that can be exploited for therapeutics against numerous autoimmune diseases is very exciting. We look forward to advancing this work though discovery into preclinical development.”  

Dr. Lustigman was responsible for spearheading a collaborative effort to generate a bioinformatics database, which predicted the therapeutic potential of this family of immune modifying proteins, and is the foundation for this work.

Research reported in this press release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number HHSN272201800035C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Celdara Medical, LLC

Celdara Medical gives hope and health to patients by transforming academic innovations into medicines with the potential to cure the world’s most challenging diseases. Celdara Medical is a recognized leader with a rich stable of discoveries, developed in concert with premiere research institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their institutions, and provide the developmental, financial, and business acumen to bridge the gaps between discovery and clinical impact. With robust funding options, operations in greater Boston, NYC, and Washington, DC, growing affiliates in Seattle and Indianapolis, a wealth of opportunities in our pipeline, and partnerships with industry leaders worldwide, Celdara Medical navigates the path from science to medicine, accelerating innovation to improve human health.

 

About Lindsley F. Kimball Research Institute
Lindsley F. Kimball Research Institute (LFKRI) is the research branch of New York Blood Center Enterprises. Since its establishment in 1964, LFKRI's research efforts have paved the way for new blood-related products, techniques, and therapies. The Institute's commitment to groundbreaking research has resulted in numerous landmark patents and licenses. LFKRI’s areas of blood-related research include transfusion medicine, hematology, infectious disease, epidemiology, and cellular therapy. Further information about Lindsley F. Kimball Research Institute is available at https://nybloodcenter.org/lindsley-f-kimball-research-institute/.